McMillen Kerry K, Schmidt Erin M, Storer Barry E, Bar Merav
1 Seattle Cancer Care Alliance , Seattle, Washington.
Metab Syndr Relat Disord. 2014 Sep;12(7):367-71. doi: 10.1089/met.2014.0051. Epub 2014 Jul 9.
Improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) enables us to learn more about potential late complications after HCT, one of which is metabolic syndrome. There are no studies investigating the prevalence or development of metabolic syndrome within the first year post-HCT in adult myeloablative transplant recipients.
In this retrospective study, we evaluated the prevalence of and risk factors associated with metabolic syndrome early post-HCT in human subjects. Due to lack of complete information regarding all the factors that define metabolic syndrome, we evaluated metabolic characteristics using available objective data referred to as modified metabolic syndrome (MMS). The cohort included 785 patients.
We demonstrated that the incidence of MMS was 34% pre-HCT, 48% at day 80 post-HCT, and 40% at 1 year post-HCT. MMS at day 80 post-HCT was predictive of having MMS at 1 year post-HCT.
These results support the need for nutrition and lifestyle intervention to prevent and treat metabolic abnormalities among patients who survive the acute transplant period.
异基因造血细胞移植（allo-HCT）后生存率的提高使我们能够更多地了解HCT后的潜在晚期并发症，其中之一是代谢综合征。尚无研究调查成人清髓性移植受者HCT后第一年内代谢综合征的患病率或发展情况。
在这项回顾性研究中，我们评估了人类受试者HCT后早期代谢综合征的患病率及相关危险因素。由于缺乏关于定义代谢综合征的所有因素的完整信息，我们使用称为改良代谢综合征（MMS）的可用客观数据评估代谢特征。该队列包括785名患者。
我们证明，HCT前MMS的发生率为34%，HCT后80天为48%，HCT后1年为40%。HCT后80天的MMS可预测HCT后1年发生MMS。
这些结果支持需要进行营养和生活方式干预，以预防和治疗度过急性移植期的患者的代谢异常。
